This segment focuses on the research, development, and clinical evaluation of CD47 blocking therapies, primarily ALX148. ALX148 is designed to block the CD47 protein, which is overexpressed on cancer cells, allowing the immune system to recognize and eliminate them. Research and development activities include preclinical studies, Phase 1b/2 clinical trials for myelodysplastic syndromes, acute myeloid leukemia, non-Hodgkin's lymphoma, and various solid tumors like head and neck squamous cell carcinoma, HER2-positive gastric/gastroesophageal junction carcinoma, and HER2-expressing breast cancer. The technology utilizes monoclonal antibodies to target CD47. The therapeutic areas covered are diverse, targeting cancers with high unmet medical needs. The patient impact is significant, offering potential for improved outcomes and survival rates. Market positioning is in the competitive immuno-oncology space, with a focus on a differentiated mechanism of action. Future opportunities include expanding clinical trials and exploring combination therapies. Regulatory and clinical aspects involve navigating FDA approval processes and conducting rigorous clinical trials. Partnerships with companies like Merck and Zymeworks are crucial for advancing clinical development and expanding the therapeutic reach of ALX148.

This segment is dedicated to the development of ALTA-002, a SIRPa TRAAC (T cell receptor activating antibody conjugate) designed to engage both the innate and adaptive immune responses to cancer. Research and development activities include preclinical studies and exploring the potential of ALTA-002 in various cancer indications. The technology involves utilizing SIRPa TRAACs to enhance the immune response against cancer cells. The therapeutic areas covered include a broad range of solid tumors. The patient impact aims to improve the efficacy of cancer treatments by stimulating the immune system. Market positioning is in the competitive field of cancer immunotherapy, with a focus on innovative approaches to engage the immune system. Future opportunities include advancing ALTA-002 into clinical trials and exploring combination therapies. Regulatory and clinical aspects involve preclinical studies and clinical trial design. Partnerships with Tallac Therapeutics are essential for the development, manufacturing, and commercialization of this novel class of cancer immunotherapeutics.